Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Psychedelic clinical research & trials stories

Oct 14, 2026

Compass Pathways CEO says company will 'go slow before we go fast' ahead of FDA submission

Compass Pathways CEO Kabir Nath stated the psychedelics company will take a measured approach as it prepares to complete submission of its psychedelic therapy for FDA regulatory review this quarter. The announcement comes as the company joins mental health organizations to mark the first U.S. Treatment-Resistant Depression Awareness Day.

Oct 14, 2026·3 sources
00
Oct 4, 2026

FDA seeks public input on clinical trial design for ibogaine drug products

The U.S. Food and Drug Administration announced a request for information on approaches for designing early-phase clinical trials of ibogaine drug products, marking the first government-funded trials of the psychedelic drug to treat opioid addiction and post-traumatic stress disorder. The agency is seeking public comments, data, and feedback on safety protocols for the studies.

Oct 4, 2026·3 sources
00

FDA advances first government-funded ibogaine clinical trials for opioid addiction and PTSD

U.S. health officials are advancing the first government-funded clinical trials of the psychedelic drug ibogaine to treat opioid addiction and post-traumatic stress disorder. The FDA announced Monday it is seeking public feedback on safety rules for the studies.

Oct 4, 2026·6 sources
00
Sep 18, 2026

Compass Pathways prepares psychedelic drug launch following J&J's ketamine strategy

Compass Pathways executives revealed plans to model their upcoming psychedelic treatment launch after Johnson & Johnson's strategy for Spravato, the ketamine nasal spray, as the FDA considers approval. The move comes as psychedelic therapeutics face a critical juncture following Lykos' failed MDMA therapy approval in 2024.

Sep 18, 2026·2 sources
00
Sep 17, 2026

Xenon Pharmaceuticals pauses depression drug trials over neuropsychiatric side effects

Xenon Pharmaceuticals temporarily halted new patient enrollment in clinical studies of its experimental depression drug following reports of mental health-related adverse events, causing shares to fall.

Sep 17, 2026·3 sources
00
Sep 14, 2026

Definium's LSD-based drug succeeds in third Phase 3 anxiety trial

Definium Therapeutics reported that its oral LSD-based treatment DT120 reduced symptoms of generalized anxiety disorder in a second successful late-stage study, marking the company's third Phase 3 win this year for the candidate.

Sep 14, 2026·2 sources
00
Sep 9, 2026

FDA suggests regulatory flexibility for assessing psychedelic therapies

The FDA indicated openness to innovative approaches for studying psychedelic therapies, including the use of comparators other than placebo, signaling potential regulatory accommodation for this emerging treatment class.

Sep 9, 2026·2 sources
00
Aug 12, 2026

Definium reports positive Phase 3 results for single-dose DT120 in generalized anxiety disorder

Definium Therapeutics announced its experimental LSD-based pill significantly reduced anxiety symptoms in a late-stage study, meeting the trial's main goal. The results mark the company's second major win in two months and sent shares up more than 20% in premarket trading.

Aug 12, 2026·2 sources
00
Aug 7, 2026

Clinical trial links ketamine's rapid anti-suicidal effects to morning cortisol surge

A recent clinical trial found that a single dose of ketamine increases morning cortisol levels in suicidal patients for up to 24 hours, potentially explaining the drug's rapid antidepressant and anti-suicidal effects. The finding adds to understanding of ketamine's therapeutic mechanisms beyond its original use as an anesthetic.

Aug 7, 2026·4 sources
00
Aug 6, 2026

UK's First Publicly Funded Trial Shows Psilocybin Significantly Improves Treatment-Resistant Depression

A randomized controlled trial conducted through the NHS in England found that a single dose of psilocybin, the active compound in magic mushrooms, produced significant improvements in depression symptoms among 60 adults with treatment-resistant major depressive disorder compared to placebo, with good tolerability.

Aug 6, 2026·4 sources
00
Aug 5, 2026

Scientists Advance Understanding of Psychedelic Mechanisms Through New Research Tools and Theories

Researchers have developed engineered mouse models for studying psychedelic drug actions, proposed a new neurobiological theory called 'apical hypercontextualisation' to explain altered perception, and identified psychedelic candidates that may reduce side effects while maintaining therapeutic benefits.

Aug 5, 2026·3 sources
00

German Study Finds Cannabis-Derived Dronabinol Significantly Reduces Nightmares in PTSD Patients

A randomized controlled trial in Germany found that dronabinol, a cannabis-derived THC medication, significantly decreased nightmares in patients with post-traumatic stress disorder in a double-blind study published in Nature Medicine.

Aug 5, 2026·3 sources
00
Jul 31, 2026

MD Anderson researchers identify shared neuroimmune mechanisms in rapid-acting antidepressants

Scientists at The University of Texas MD Anderson Cancer Center have discovered common neuroimmune signatures that may explain how rapid-acting antidepressants like ketamine and psychedelics work to reduce symptoms in treatment-resistant depression.

Jul 31, 2026·1 source
00
Jul 26, 2026

Phase 2 Clinical Trial Shows THC-CBD Combination Rapidly Reduces Agitation in Advanced Dementia Patients

The LiBBY clinical trial found that a combination of CBD and THC rapidly and significantly reduced agitation in hospice-eligible dementia patients, with nearly 90% of participants showing behavioral improvement in the nationwide study.

Jul 26, 2026·3 sources
00
Jul 15, 2026

Eli Lilly nears deal to acquire psychedelic drugmaker AtaiBeckley

Eli Lilly is in advanced talks to acquire AtaiBeckley, a psychedelic medicine company, with a deal potentially announced this week. The acquisition underscores growing interest from major pharmaceutical companies in psychedelic therapies.

Jul 15, 2026·2 sources
00
Jul 7, 2026

Compass Pathways' Psilocybin Therapy Shows Durable Benefits for Treatment-Resistant Depression in Pivotal Trial

Compass Pathways reported results from a pivotal study showing its psilocybin-based therapy demonstrated long-lasting benefits for treatment-resistant depression, though investor reaction was mixed as shares fell nearly 10% on the data.

Jul 7, 2026·2 sources
00
Jun 22, 2026

Definium's LSD-Based Pill Reduces Depression Symptoms in Late-Stage Trial

Definium Therapeutics reported that a single dose of its LSD-based experimental pill significantly reduced symptoms of major depression in patients in a late-stage trial, sending shares higher. The data brings the drug closer to potential FDA approval.

Jun 22, 2026·2 sources
00
May 5, 2026

Study finds single dose of psilocybin causes measurable brain changes in first-time users

Research published in Nature Communications shows that a 25mg dose of psilocybin induced both acute functional changes (detected via EEG one hour later) and enduring anatomical changes (detected via DTI one month later) in 28 healthy adults experiencing their first psychedelic trip.

May 5, 2026·3 sources
00
Apr 19, 2026

Trump Signs Executive Order to Accelerate Psychedelic Drug Reviews Including Controversial Ibogaine

President Trump signed an executive order directing the FDA to expedite reviews of psychedelic drugs including ibogaine, which has been embraced by combat veterans but remains controversial. The order was signed alongside podcast host Joe Rogan.

Apr 19, 2026·3 sources
00
Apr 18, 2026

Trump Signs Executive Order to Expedite Psychedelic Drug Review and Reclassification

President Trump signed an executive order directing the FDA to expedite reviews of breakthrough psychedelic therapies for PTSD, depression, and trauma, and to reevaluate their status as controlled substances. The order targets substances including psilocybin.

Apr 18, 2026·3 sources
00

Top claims

  • ▪Compass Pathways expects COMP360 to be subject to an FDA risk evaluation and mitigation strategy (REMS) upon approval and is investing in provider training for drug administration.
  • ▪In Compass Pathways Phase 3 trials, roughly 40% of treatment-resistant depression patients experienced a clinically meaningful response after receiving two doses of COMP360 three weeks apart.
  • ▪The Treatment-Resistant Depression Awareness Day campaign is supported by the National Alliance on Mental Illness, Mental Health America, and the Depression and Bipolar Support Alliance.

People involved

Joe RoganDonald Trump

Subtopics

Mental Health & Wellbeing12Psychedelic policy & regulation11Drug Approval and Clinical Trials9Drug Policy, Pricing & Approval9Depression8Stress, Burnout & Well-being7Psychedelic renaissance6Psilocybin4Clinical evaluation3Clinical Trial Design & Evaluation3Ketamine3LSD3Mental health3Pharma3Trauma & PTSD3Addiction & recovery2Addiction and Harm Reduction2Anxiety2Ibogaine2Neuroplasticity2Psychedelic harm reduction2Psychedelic-assisted therapy2Psychedelics for depression2Psychedelics for PTSD2

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories